138 related articles for article (PubMed ID: 25662844)
1. Drug composition matters: the influence of carrier concentration on the radiochemical purity, hydroxyapatite affinity and in-vivo bone accumulation of the therapeutic radiopharmaceutical 188Rhenium-HEDP.
Lange R; de Klerk JMH; Bloemendal HJ; Ramakers RM; Beekman FJ; van der Westerlaken MML; Hendrikse NH; Ter Heine R
Nucl Med Biol; 2015 May; 42(5):465-469. PubMed ID: 25662844
[TBL] [Abstract][Full Text] [Related]
2. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
ter Heine R; Lange R; Breukels OB; Bloemendal HJ; Rummenie RG; Wakker AM; de Graaf H; Beekman FJ; van der Westerlaken MM; Malingré MM; Wielders JP; van den Berg L; Hendrikse NH; de Klerk JM
Int J Pharm; 2014 Apr; 465(1-2):317-24. PubMed ID: 24560635
[TBL] [Abstract][Full Text] [Related]
3. Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical rhenium-188-HEDP.
Lange R; Ter Heine R; van der Gronde T; Selles S; de Klerk J; Bloemendal H; Hendrikse H
Eur J Pharm Sci; 2016 Jul; 90():96-101. PubMed ID: 26772897
[TBL] [Abstract][Full Text] [Related]
4. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes.
Lin WY; Hsieh JF; Lin CP; Hsieh BT; Ting G; Wang SJ; Knapp FF
Nucl Med Biol; 1999 May; 26(4):455-9. PubMed ID: 10382850
[TBL] [Abstract][Full Text] [Related]
5. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones.
Uehara T; Jin ZL; Ogawa K; Akizawa H; Hashimoto K; Nakayama M; Arano Y
Nucl Med Biol; 2007 Jan; 34(1):79-87. PubMed ID: 17210464
[TBL] [Abstract][Full Text] [Related]
6. Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.
Deilami-Nezhad L; Moghaddam-Banaem L; Sadeghi M
Appl Radiat Isot; 2017 Nov; 129():108-116. PubMed ID: 28843158
[TBL] [Abstract][Full Text] [Related]
7. Preparation, stability studies and pharmacological behavior of [186Re]Re-HEDP.
Kothari K; Pillai MR; Unni PR; Shimpi HH; Noronha OP; Samuel AM
Appl Radiat Isot; 1999 Jul; 51(1):51-8. PubMed ID: 10376321
[TBL] [Abstract][Full Text] [Related]
8. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
[TBL] [Abstract][Full Text] [Related]
9. A Freeze-Dried Kit for the Preparation of (188)Re-HEDP for Bone Pain Palliation: Preparation and Preliminary Clinical Evaluation.
Mallia MB; Shinto AS; Kameswaran M; Kamaleshwaran KK; Kalarikal R; Aswathy KK; Banerjee S
Cancer Biother Radiopharm; 2016 May; 31(4):139-44. PubMed ID: 27183437
[TBL] [Abstract][Full Text] [Related]
10. Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases.
Hsieh BT; Hsieh JF; Tsai SC; Lin WY; Wang SJ; Ting G
Nucl Med Biol; 1999 Nov; 26(8):973-6. PubMed ID: 10708313
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-188 Hydroxyethane 1,1-Diphosphonic Acid (HEDP) for Bone Pain Palliation Using BARC-HEDP Kits versus Pars-HEDP Kits: A Comparison on Preparation and Performance Aspects at Hospital Radiopharmacy.
Ramakurup REK; Chirayil V; Pandiyan A; Mallia MB; Kameswaran M; Shinto A; Dash A
Indian J Nucl Med; 2018; 33(4):302-305. PubMed ID: 30386051
[TBL] [Abstract][Full Text] [Related]
12. Capillary electrophoretic and thin-layer chromatographic characterization of rhenium complexation with 1-hydroxyethylidenediphosphonic acid.
Koudelková M; Jedináková-Krízová V
J Chromatogr A; 2003 Mar; 990(1-2):317-23. PubMed ID: 12685611
[TBL] [Abstract][Full Text] [Related]
13. 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
El-Mabhouh AA; Mercer JR
Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1240-8. PubMed ID: 18265977
[TBL] [Abstract][Full Text] [Related]
14. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
Ogawa K; Mukai T; Arano Y; Ono M; Hanaoka H; Ishino S; Hashimoto K; Nishimura H; Saji H
Bioconjug Chem; 2005; 16(4):751-7. PubMed ID: 16029015
[TBL] [Abstract][Full Text] [Related]
15. Gastric uptake during Re-186 HEDP bone scintigraphy.
Limouris GS; Skukla SK
Anticancer Res; 1997; 17(3B):1779-81. PubMed ID: 9179234
[TBL] [Abstract][Full Text] [Related]
16. Rhenium-188(Sn)HEDP for treatment of osseous metastases.
Maxon HR; Schroder LE; Washburn LC; Thomas SR; Samaratunga RC; Biniakiewicz D; Moulton JS; Cummings D; Ehrhardt GJ; Morris V
J Nucl Med; 1998 Apr; 39(4):659-63. PubMed ID: 9544677
[TBL] [Abstract][Full Text] [Related]
17. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
18. Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.
Lin WY; Lin CP; Yeh SJ; Hsieh BT; Tsai ZT; Ting G; Yen TC; Wang SJ; Knapp FF; Stabin MG
Eur J Nucl Med; 1997 Jun; 24(6):590-5. PubMed ID: 9169563
[TBL] [Abstract][Full Text] [Related]
19. Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study.
Lange R; Overbeek F; de Klerk JM; Pasker-de Jong PC; van den Berk AM; Ter Heine R; Rodenburg CJ; Kooistra A; Hendrikse NH; Bloemendal HJ
Nuklearmedizin; 2016 Sep; 55(5):188-95. PubMed ID: 27443809
[TBL] [Abstract][Full Text] [Related]
20. (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Lam MG; Bosma TB; van Rijk PP; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1425-33. PubMed ID: 19319526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
